Microcystin-leucine-arginine (MCLR) is an environmental toxin from harmful algae, which has been linked to hepatotoxicity with high risks associated with liver disease. In this study, we explored the role of MCLR in NF-κB and mitogen-activated protein kinase (MAPK) signaling pathways, which are important in regulating inflammatory and immune responses, in human hepatoma cell line HepG2 and primary mouse hepatocytes (PMHs). By in vitro cell-free and luciferase reporter systems, Western blotting with antiphospho-inhibitory protein of NF-κB (IκBα)/c-Jun N-terminal kinase (JNK)/extracellular signal-regulated kinase 1/2 (ERK1/2) antibody, it was found that at noncytotoxic concentrations (≤ 20nM MCLR in PMHs, 1-1000nM in HepG2), MCLR treatment alone promoted activation of NF-κB and MAPK pathways and modulated TNF-α-induced activation of the 2 pathways in both cell models. By ELISA assay, MCLR was found to induce production of proinflammatory cytokine IL-6 in PMHs. At cytotoxic concentrations (≥ 50nM MCLR in PMHs), MCLR dramatically reduced cell viability and damaged cell morphology in PMHs, as determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay and transmission electron microscopy analysis. These results suggest that MCLR below 20nM has significant immunomodulatory activities through activation of NF-κB and MAPK signaling pathways, and PMHs are more sensitive to MCLR-induced cytotoxicity than HepG2. To our knowledge, this is the first report showing the immunomodulatory role of MCLR in hepatocytes. Our results provide a better understanding of the molecular mechanisms underlying MCLR-induced hepatotoxicity.
Microcystins (MCs) is a family of environmental toxins from cyanobacteria, which has posed a worldwide concern due to predominant hepatotoxicity to human health. For instance, fishermen and children have been reported to suffer hepatocellular damage from intake of MCs ranging from 2.03 to 3.90 μg per day (Chen et al., 2009; Li et al., 2011) . Of nearly 90 MCs identified, MC-leucine-arginine (MCLR) is the most contributing to hepatotoxicity induced by MCs (Pearson et al., 2010) . Many studies have been carried out on the molecular mechanisms underlying the MCLR-induced hepatotoxicity. A common theme is that MCLR can directly inhibit the activities of phosphatases PP1 and PP2A, which leads to excessive phosphorylation of proteins resulting in misregulation of cytoskeleton, cell proliferation, and apoptosis (Gan et al., 2010; Komatsu et al., 2007; Sun et al., 2011) . MCLR also directly interacts with mitochondria and induces production of reactive oxygen species (Wei et al., 2008) . However, the molecular mechanism of MCLR-induced hepatotoxicity is not fully understood.
Recent evidence has shown that leukocyte infiltration occurs in MCLR-exposed rat liver, which indicates that MCLR could be involved in regulation of inflammatory response (Kujbida et al., 2008) . Actually, MCLR has been found to modulate immune responses and inflammatory cytokine expression in several animal models, such as fish and mouse. In carp (Cyprinus carpio L.), MCLR inhibited phagocytosis, induced lymphocyte necrosis, and dysregulated expression of inflammatory cytokines such as interleukin (IL)-1β and tumor necrosis factor (TNF)-α in blood and head kidney leukocytes (Rymuszka, 2012; Rymuszka and Adaszek, 2012) . In mouse macrophages, MCLR downregulated lipopolysaccharide (LPS)-induced inducible nitric oxide synthase (iNOS), IL-1β, and TNF-α messenger RNA levels, which elicited an immunosuppressive effect (Chen et al., 2004) . Although MCLR dysregulates cytokine expression in immunocytes, little is known about its immunomodulatory role in hepatocytes. Hepatocytes could secrete systemically acting inflammatory mediators, including cytokines and chemokines (Nishitsuji et al., 2013) . Therefore, considering hepatocytes are the main target cells of MCLR, it is vital to investigate the immunomodulatory role of MCLR in hepatocytes.
toxicological sciences 136(1), 86-96 2013 doi:10 .1093/toxsci/kft180 Advance Access publication August 22, 2013 Inflammatory and immune responses are regulated by multiple signaling pathways. Among which the NF-κB and mitogenactivated protein kinase (MAPK) signaling pathways, which include the extracellular signal-regulated kinase 1/2 (ERK1/2), p38, and c-Jun N-terminal kinase (JNK) pathways, are critical participants in cellular stress responses and modulate a variety of inflammatory responses (DiDonato et al., 2012; Johnson and Lapadat, 2002) . Recently, the regulatory effects of MCLR on cellular signaling pathways have been received much attention. It has shown that MCLR is involved in activation of ERK1/2, JNK, and p38 signaling pathways in various cellular activities, such as proliferation, apoptosis, cytoskeleton reorganization, in different cell models, including human embryonic kidney 293 cells (HEK 293), monkey-kidney-derived cell line (Vero-E6), and rat neuroendocrine cells (PC12; Dias et al., 2010; Komatsu et al., 2007; Meng et al., 2011) . Besides, Zhang et al. (2012) showed that MCLR activates NF-κB leading to its enhanced nuclear translocation and DNA-binding ability in human melanoma cell line MDA-MB-435. These suggested that MCLR can exert its effects on cellular signaling pathways. However, whether MCLR regulates NF-κB and MAPK pathways in hepatocytes remains to be elucidated.
Primary hepatocytes, which better simulate the in vivo situation, were found to be more susceptible to MCLR-induced cytotoxicity (Fischer et al., 2010) . The expression level of organic anion-transporting polypeptide 1B1 (OATP1B1, an MCLR transporter) is higher in primary human hepatocytes than in HepaRG cell lines, which may contribute to the higher sensitivity of primary hepatocytes (Ulvestad et al., 2012) . In addition, the activities of phase I and II drug-metabolizing enzymes are normal in primary hepatocytes, making them more propitious to the toxicity evaluation of environmental pollutants (Guillouzo, 1998; Rubiolo et al., 2012) . Previous studies have revealed that MCLR induces cytoskeleton disruption and oxidative DNA damage in primary rat hepatocytes (Ding et al., 2001; Maatouk et al., 2004) . However, the immunomodulatory role of MCLR in primary mouse hepatocytes (PMHs) is not clear.
We hypothesized that chronic exposure to MCLR, especially at lower doses, has immunomodulatory activities, which could contribute to MCLR-induced hepatotoxicity. Here, as the first step, we tried to establish the connection between MCLR and inflammation in hepatocytes. By using HepG2 cells, which display the morphology and biochemical activities of healthy hepatocytes and is a commonly used in vitro model to study cellular effects of MCLR and PMHs, we explored a variety of novel methodologies to examine the dose-dependent activation of NF-κB and MAPK pathways and the induction of IL-6 in hepatocytes after exposure to cytotoxic and noncytotoxic concentrations of MCLR with or without TNF-α, which simulate likely single and combined exposure scenarios.
MATERIALS ANd METHOdS
Reagents. MCLR was purchased from Alexis Biochemicals (Enzo Life Sciences, Shanghai, China; purity ≥ 95%, by high-performance liquid chromatography) and dissolved in deionized water to 1000μM as stock solution. TNF-α and anti-inhibitory protein of NFκB (IκBα) antibody were prepared in our laboratory according to standard methods (Celis, 2006) . Rabbit monoclonal phospho-IκBα (Ser32) antibody was obtained from Cell Signaling Technology (Danvers, Massachusetts). Anti-ERK1/2 and anti-phospho-ERK1/2 (Thr202/ Thr204) antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, California). Antibodies against p38, phospho-p38 (Thr180/Tyr182), JNK, phospho-JNK (Thr183/Tyr185), α-tubulin, and β-actin were purchased from Epitomics (Burlingame, California). Anti-rabbit and anti-mouse secondary antibodies were purchased from Sigma (Shanghai, China).
The pGL2-based NF-κB luciferase reporter plasmid and renilla pRL-TK plasmid were obtained from Promega Corporation (Madison, Wisconsin). "Firefly" and renilla luciferase substrates were purchased from Sangon Biotech (Shanghai, China) and Promega Corporation, respectively. Firefly luciferase assay buffer contained 25mM glycylglycine, 15mM potassium phosphate, 15mM magnesium sulfate, 4mM ethylene glycol tetraacetic acid, 1mM ATP, 1mM dithiothreitol (DTT), 0.1mM firefly luciferase substrates. Renilla luciferase assay buffer contained 1× PBS, 250mM sodium chloride, 2mM EDTA, 10 μg/ml renilla luciferase substrates. The digestion buffer used in isolating PMHs contained 3mM potassium chloride, 0.13M sodium chloride, 1mM NaH 2 PO 4 ·2H 2 O, 10mM glucose, and 10mM 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES). All chemicals and reagents without special indication were from Sigma (Shanghai, China).
Cell culture. PMHs from 12-week-old male C57BL/6 mice (23-30 g; Slac Laboratory Animal, Shanghai, China) were isolated by a 2-step collagenase perfusion (Oldham et al., 1979) . The mouse liver was sequentially perfused with buffer A (digestion buffer containing 0.5mM EGTA), buffer B (digestion buffer), and buffer C (digestion buffer containing 0.1 mg/ml collagenase IV and 5mM CaCl 2 ) through the inferior vena cava using a 22-gauge catheter (Terumo, New Jersey). Digested cells were suspended in 50 ml PBS and passed through a 100-μm nylon mesh (Fisher, Pittsburgh, Pennsylvania) . After centrifugation at 30 × g for 2 min, the cell pellet was collected to prepare hepatocytes. Cells were resuspended in Dulbecco's Modified Eagle's Medium (DMEM; KeYi, Hangzhou, China) supplemented with 10% fetal bovine serum (FBS, vol/ vol) (Gibco, Shanghai, China), penicillin-streptomycin (20 U/ml and 20 μg/ ml, respectively; Invitrogen, Shanghai, China), and 1% amphotericin (vol/vol) (Gibco). Cell number and viability were measured by trypan blue (Invitrogen) staining and counted by a hemocytometer (Fisher). The isolated cells maintained 90% viability and were placed in 12-well plates (Corning, Shanghai, China) coated with type I rat tail collagen (BD Biosciences, San Jose, California). HepG2 cell line was obtained from the Cell Bank of the Chinese Academy of Science (Shanghai, China) and cultured in DMEM containing 10% FBS (vol/vol) and 1% penicillin-streptomycin. All cells were maintained at 37°C in a humidified atmosphere containing 5% CO 2 .
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide-based cell viability assay. Cytotoxicity induced by MCLR was assessed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay according to the manufacturer's protocol (Beyotime, Haimen, China). One hundred microliters of freshly isolated PMHs and HepG2 cells solution were distributed into 96-well plates (Corning) at a density of 5 × 10 4 cells/ml. Cells were allowed to settle for 20 h prior to MCLR addition (0, 1, 10, 50, 100, 500, and 1000nM final concentration in wells) and cultured for 24 h. Following exposure to MCLR, 10-μl MTT (5 mg/ml) were added to the medium for an additional 4 h. Formed formazan was dissolved in 100 μl formazan solution. The absorbance of each well was measured at 570 nm using the model 680 microplate reader (BioRad, Hercules, California). Triplicates were done for each treatment condition, and data (mean ± SD) are presented as percentage relative to the controls. Cells without MCLR exposure were used as controls and set at 100% viability.
Protein content analysis.
Freshly isolated PMHs were settled in 12-well plates at a density of 5 × 10 4 cells/ml. Cells were treated with 1-100nM MCLR for 24 h for dose-dependent assays or for 3-24 h at the concentration of 25nM MCLR for time-course assays. Cells were lysed in buffer D (50mM Tris-HCl, pH 7.4, 150mM NaCl, 0.5% NP-40, 10% glycerol, 1mM DTT, 1mM PMSF, and 10 μg/ml leupeptin), and the supernatant (cytosolic fraction) was collected ZHANG, CHEN, AND XIA after centrifugation at 14 000 × g for 10 min at 4°C. Protein concentration was measured by a Bradford kit (Sangon, Shanghai, China). Three replicates were set for each treatment condition and data (mean ± SD) are presented as percentage relative to the controls.
Western blotting assay. Cell lysates were mixed with SDS sample buffer and boiled for 5 min. Ten micrograms of protein were loaded onto a 10% SDSpolyacrylamide gel, separated by electrophoresis, and then electroblotted onto PVDF membranes (Millipore, Billerica, Massachusetts). Membranes were incubated for 2 h with primary antibodies (phosphorylated and total forms of anti-IκBα, anti-ERK1/2, anti-p38 and anti-JNK, and anti-IKKα, anti-α-tubulin and anti-β-actin), followed by alkaline phosphatase-labeled secondary antibodies for 2 h. Bands were visualized with the NBT-BCIP kit (Sangon).
Cell-free in vitro NF-κB activation assay. To explore the effect of MCLR on NF-κB activation, a cell-free in vitro NF-κB activation assay was conducted according to a published protocol (Deng et al., 2000) . Briefly, total cellular protein was extracted from HepG2 cells, and the supernatant was collected after centrifugation at 100 000 × g for 1 h at 4°C (termed here S100). The assay setup contained S100 (10×), ATP buffer (10×, 50mM Tris-Cl, pH7.4, 20mM ATP, 50mM magnesium chloride, 10mM DTT), ddH 2 O, and 0-100nM MCLR with or without TNF receptor-associated factor 6 (10×) (positive control) to a FIG. 1. Microcystin-leucine-arginine (MCLR) induces cytotoxicity in primary mouse hepatocytes (PMHs) but not in HepG2 cell line. (A) Cell viability of PMHs and HepG2 cells exposed to MCLR (1-1000nM) for 24 h, evaluated by the MTT assay. (B) Dose-dependent and time-dependent effect of MCLR on protein content of PMHs evaluated by the Bradford assay after exposure to MCLR (1-100nM) for 24 h or to MCLR (25nM) for 3-24 h, respectively. Data are presented as mean ± SD (n = 3); *p < .05, **p < .01, ***p < .001 compared with control.
IMMUNOMODULATION OF MCLR IN HEPATOCYTES
total volume of 10 μl. The mixture was incubated at 30°C for 1 h. SDS sample buffer was added, followed by boiling for 5 min to stop the reaction. To check activation of NF-κB, IκBα and phospho-IκBα were detected by Western blot analysis with specific antibodies.
In vivo NF-κB and MAPK activation assays. Activation of NF-κB and MAPK signaling pathways in PMHs and HepG2 cells was determined by Western blot using phospho-specific antibodies. Cells were plated into 12-well plates and treated with 1-20nM (PMHs) or 1-1000nM (HepG2) MCLR for 24 h. To investigate the combined effect of MCLR and TNF-α, cells were pretreated with MCLR for 23 h and then treated with TNF-α (5 ng/ml) for 0-60 min. After treatment, cells were lysed in 50 μl lysis buffer D and used for Western blot assay.
A phospho-specific primary antibody against IκBα was used in the Western blot to detect NF-κB activation. Phospho-specific primary antibodies against ERK1/2, p38, or JNK were used for the detection of activation of ERK1/2, p38, and JNK pathways, respectively. Primary antibodies against IκBα, ERK1/2, p38, and JNK were also used for detection of respective total proteins.
For each protein detected by Western blot, phosphorylation level relative to its total level (fold of control after normalization against total protein content and 3 replicates for each treatment condition) was determined by Quantity One software (Bio-Rad).
Luciferase reporter-based NF-κB activation assay. NF-κB activation induced by MCLR and TNF-α was also examined in HepG2 cells by luciferase reporter assay. HepG2 cells were plated into 12-well plates and transiently transfected with 20 ng of 3× NF-κB-luciferase (firefly) reporter and 5 ng of renilla luciferase (transfection efficiency control) constructs using the polyethylenimine reagent according to the manufacturer's protocols (Polysciences, Warrington, Pennsylvania). The media were replaced 4 h after transfection with media containing 0, 1, 10, 100, or 1000nM MCLR. For the TNF-α treatment group, cells were treated with MCLR for 6 h and then stimulated with TNF-α (5 ng/ml) for 18 h. After the incubation, cells were lysed with luciferase reporter lysis buffer E (0.5% 3-((3-cholamidopropyl)dimethylammonio)-1-propanesulfonate, 25mM glycylglycine, 15mM magnesium sulfate, 4mM EGTA, 1mM DTT, 1mM PMSF). Ten microliters of lysates were transferred into 96-well plates, and 50 μl firefly and renilla luciferase assay buffer was added to each well before reading. Luciferase activities were measured on the DLReady luminometer (Berthold Technologies, Bad Wildbad, Germany). Triplicates were done for each exposure condition, and data are presented as fold activation of NF-κB relative to the control. 
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ELISA for measurement of IL-6 production. PMH cells were distributed into 24-well plates (Corning) at a density of 5 × 10 4 cells/ml. Cells were allowed to settle for 24 h before exposure to 1-50nM MCLR for 24 h, or 20nM MCLR for 6-48 h. To investigate the combined effect of MCLR and TNF-α, cells were pretreated with MCLR as mentioned above and then stimulated by TNF-α (5 ng/ml) for 24 h. The cell culture supernatants were collected and assayed by the Mouse IL-6 ELISA Kit (eBioscience, San Diego, California) according to the manufacturer's instructions. Three replicates were performed for each treatment condition. Absorbance of each well was measured at 450 nm using the model 680 microplate reader with a 570 nm reference wavelength. The concentration of IL-6 was calculated from the IL-6 standard curve.
Transmission electron microscopy. Ultrastructural changes of PMHs were observed by a transmission electron microscope (TEM; JEM-1230, JEOL, Tokyo, Japan). After exposure to MCLR (0, 25, 50, or 100nM) for 24 h, cell samples were fixed in 2.5% glutaraldehyde at 4°C overnight. Next, cell pellets were washed with PBS (0.1M, pH 7.0) 3 times and postfixed in 1% osmium tetroxide at room temperature for another 2 h. Following the washing procedure, samples were dehydrated under a graded series of ethanol solutions of increasing concentrations (50%, 70%, 80%, 90%, and 95%) and embedded with Epon812 resin and acetone. Ultrathin sections were cut by EM UC7 (LEICA, Solms, Germany) and then stained with uranyl acetate and lead citrate for examination under the TEM.
Statistical analysis. Data were analyzed using SPSS 16.0 software and expressed as mean ± SD of the 3 replicates of each treatment. Differences between the control and MCLR treatment groups were determined by 1-way ANOVA followed by least significant difference (LSD) for multiple comparisons. A 2-way ANOVA with LSD test was used for assessment of the differences between the combined exposure to MCLR and TNF-α versus the exposure to TNF-α alone. Values of p less than .05 were considered statistically significant.
RESuLTS

The Sensitivity of PMHs and HepG2 Cells Exposed to MCLR
To explore the relationship between MCLR and NF-κB/ MAPK pathways, we sought to use PMHs, which express high level of OATP1B2 responsible for uptake of MCLR and hence should have measureable responses to MCLR treatment. In general, acute exposure of MCLR can have opposite cellular effects depending on the concentration used. To find the concentration range of MCLR that would not cause lots of cell damage and cell death, we performed a dose-response analysis with freshly isolated PMHs. After 24 h of incubation, PMHs started to show dramatic rounding up and detachment when the concentration of MCLR was 100nM or higher (data not shown), indicating a severe effect on cell viability. Cell viability was quantified by the MTT assay. MCLR decreased the viability of PMHs in a dose-dependent manner (Fig. 1A) . Significant change was observed at a concentration as low as 50nM. At this concentration, the cell viability was reduced to 67.30% ± 0.57% of control. In agreement with the cell viability, MCLR treatment also reduced the protein content in PMHs in a dose-dependent and time-dependent manner (Fig. 1B) . In contrast, MCLR did not decrease HepG2 cell viability when treated for 24 h at the concentration range of 1-1000nM (Fig. 1A) . These data show that PMHs are highly sensitive to MCLR treatment, and MCLR induces cytotoxicity when its concentration reaches a certain level. Based on these, we defined PMHs concentrations at 20nM and below (0-20nM) as noncytotoxic and concentrations above 20nM as cytotoxic. To HepG2 cells, 1-1000nM of MCLR is not cytotoxic at all. 
FIG. 4.
Effect of microcystin-leucine-arginine (MCLR) on the NF-κB and mitogen-activated protein kinase pathways in primary mouse hepatocytes. (A) Cells were treated with 1-20nM MCLR for 24 h. In the combined experiment, cells were treated with 1-20nM MCLR for 23 h before the addition of TNF-α (5ng/ml) for the indicated times. Western blot was performed with the indicated antibodies and quantified as in the graph. (B) Cells were collected after treatment with 1-100nM MCLR for 24 h or 25nM MCLR for 3-24 h. Equal amounts of protein were loaded. Western blot was performed with the indicated antibodies and quantified as in the graph. Dose-dependent and time-dependent protein degradation was regressed by a sigmoidal-logistic model. *p < .05, **p < .01, ***p < .001 compared with the control; #p < .05, ##p < .01 compared with the TNF-α-treated cells.
MCLR Activates the NF-κB and MAPK Pathways in a Dose-Dependent Manner and Sensitizes HepG2 Cells to TNF-α-Induced NF-κB and MAPK Activation
We next investigated whether MCLR treatment can induce activation of NF-κB and MAPK pathways. Activation of NF-κB signaling pathway involves IκBα (inhibitory protein of NF-κB) phosphorylation and its subsequent ubiquitination and proteasome-dependent degradation, followed by NF-κB translocation into the nucleus (Mercurio et al., 1997) , which then starts induction of target genes if they contain NF-κB-binding DNA sequences in the promoter region. As shown in Fig. 2A , MCLR induced IκBα phosphorylation at 60nM and higher concentrations in the in vitro cell-free NF-κB activation assay. However, in HepG2 cells, NF-κB was activated at doses higher than 300nM of MCLR (Fig. 2B) . Pretreatment with MCLR potentiated the TNF-α-induced NF-κB activation in a dose-dependent manner (Figs. 2C and D) .
We further assessed the activation of MAPKs. HepG2 cells were treated with MCLR alone or in combination with TNF-α. The results show that treatment with MCLR (1-1000nM) alone induced significant ERK1/2 phosphorylation, whereas it had no detectable effect on JNK and p38 phosphorylation, as depicted from Figure 3A . Pretreatment of MCLR for 23 h followed by TNF-α stimulation dramatically potentiated the activation of both ERK1/2 and JNK pathways in a dose-dependent manner as depicted from Figures 3B and 3C . Interestingly, pretreatment of MCLR significantly accelerated TNF-α-induced phosphorylation of ERK1/2 from 60 min to 10 min, whereas no such acceleration could be observed in enhanced JNK phosphorylation (Figs. 3B and C) . The results suggest that pretreatment of HepG2 cells with MCLR led to a state of cellular hyperresponsiveness toward subsequent stimulation with TNF-α.
NF-κB and MAPK Signaling Pathways Are Activated by Noncytotoxic Doses of MCLR but Disrupted by Cytotoxic Doses of MCLR in PMHs
Next, we explored the effects of MCLR on the NF-κB and MAPK signaling pathways in PMHs. After noncytotoxic MCLR (1-20nM) treatment, IκBα was phosphorylated and degraded at 10 and 20nM of MCLR (Fig. 4A) . JNK was also activated by MCLR in a dose-dependent manner. Furthermore, pretreatment with MCLR augmented the TNF-α-induced IκBα and JNK phosphorylation, which is consistent with the results in HepG2 cells. In contrast, significant degradation of IKKα (NF-κB pathway), ERK1/2, JNK, and p38 (MAPK pathways) occurred when cytotoxic concentrations of MCLR were used (25nM or higher; Fig. 4B ), with EC 50 values of 13.27 ± 0.08, 13.27 ± 4.26, 11.86 ± 1.01, and 14.49 ± 3.74nM, respectively. In the time-course experiment, 25nM MCLR treatment resulted in a time-dependent decrease in protein levels of IKKα, ERK1/2, p38, and JNK, in which a significant decrease occurred at 12 h. After 24 h, the protein levels of IKKα, ERK1/2, p38, and JNK decreased to 53% ± 0.16%, 29.69 ± 2.01%, 44.06% ± 3.68%, and 62.04% ± 0.68% of control, respectively.
MCLR Induces Expression of the Proinflammatory Cytokine IL-6 in a Dose-Dependent and Time-Dependent Manner
One major consequence that results from activation of NF-κB and MAPK signaling pathways is the induction of proinflammatory cytokines. We then studied the effects of MCLR on expression of the downstream proinflammatory cytokine IL-6 in PMHs, which was determined by ELISA assay. After exposure to 1-50nM of MCLR, IL-6 expression significantly increased in a dose-dependent manner reaching the maximum at 20nM, approximately 2.5-fold higher than that in the control group (Fig. 5A ). In the time-course experiment, after 20nM MCLR treatment, IL-6 expression was upregulated and sustained in the first 12 h, after which the induction level was decreased; however, the concentration of IL-6 was still higher than that in the control (Fig. 5B) . Analysis of the combined effect of MCLR and TNF-α demonstrated that MCLR pretreatment augmented the TNF-α-induced IL-6 expression at every time point tested, which peaked at 12 h (Fig. 5B) . In addition, we conducted similar IL-6 induction assay in HepG2 cells and found no detectable IL-6 production.
Cytotoxic Doses of MCLR Treatment Result in Morphological Damage of PMHs
Cell morphological damage accompanied by MCLR-induced signaling pathway disruption in PMHs was observed by TEM to explore the damaged organelles contributing to cytotoxicity. Untreated cells showed intact cell membranes, compact cytoplasm, and normal mitochondria and nuclei ultrastructures (Figs. 6a, e, and i), whereas in the treated cells, cell membranes began to bleb, and cytoplasm vacuolization occurred when the MCLR concentration was higher than 25nM . Mitochondria were the main target organelle of MCLR. Mitochondrial bilayers collapsed, and cristae and matrix were lost in a progressive and dose-dependent manner (Figs. 6f-h ). MCLR induced a prominent decrease in electron density in the nucleoplasm compared with the control (Figs. 6j and k) . Finally, the nuclear membrane was disrupted, and nuclei content was lost in the 100nM treated cells (Fig. 6l) .
dISCuSSION
This study, for the first time, reports the immunomodulatory role of the environmental toxin MCLR, through NF-κB and MAPK signaling pathways, in PMHs and HepG2 cells. We found that noncytotoxic doses of MCLR induced activation of NF-κB, JNK, and ERK1/2 in PMHs and HepG2 cells. We further determined the expression of downstream proinflammatory cytokine IL-6, which is a pleiotropic cytokine and upregulated in promyelocytic leukemia and during tumorigenesis (Hubackova et al., 2012; Park et al., 2010) . The results showed that noncytotoxic concentration of MCLR increased the expression of IL-6 in a dose-dependent and time-dependent manner in PMHs. We also noticed that high concentration (50nM) or longer exposure time (after 24 h) to MCLR decreased IL-6 production, which possibly contributes to the hepatocellular impairment by MCLR. The results are consistent with in vivo research that has indicated that a high dose of MCLR (50 μg MCLR eq/kg) suppressed IL-6 production, whereas a low dose (12.5 μg MCLR eq/kg) gradually induced IL-6 expression in the first 12 h, followed by reduced expression after 24 h (Yuan et al., 2012) . These results collectively suggest that MCLR have strong immunomodulatory activities, implying these activities could contribute to MCLR-induced hepatotoxicity, which warrants further studies in the future.
Furthermore, we wanted to investigate how MCLR might exert its effects on hepatocytes when they have already been undergoing (chronic) inflammation. There are real-life situations where people undergo chronic inflammation, such as duo to chronic HBV and HCV infection and are also exposed to MCLR at the same time. To do this, we pretreated cells with MCLR followed by TNF-α treatment, which was to induce inflammation. Our results showed that MCLR and TNF-α synergistically activated NF-κB, ERK1/2, and JNK in a dosedependent manner, indicating that MCLR exposure sensitizes hepatocytes to subsequent TNF-α stimulation, which implies that MCLR exposure followed by a second intoxication would pose a higher risk. Furthermore, pretreatment with MCLR augmented TNF-α-induced IL-6 expression within 12 h and downregulated it after 24 h in a dose-dependent manner, which indicated that MCLR induces either immunostimulatory or immunosuppressive responses depending on the exposure duration.
In addition, we explored an in vitro cell-free assay system to study the role of MCLR in NF-κB activation. To our knowledge, this is the first time such a system was explored to study environmental toxins such as MCLR, although this assay was originally reported in 2000 (Deng et al., 2000) . The cell-free in vitro NF-κB activation assay mimics NF-κB activation in vivo and can be detected by IκBα phosphorylation using its phospho-specific antibody. This system has 2 advantages. (1) There is no plasma membrane barrier, so the concentrations used are actual concentrations to which proteins are exposed. (2) This in vitro assay is very quick and can be done in 2 h.
In conclusion, the present study demonstrated that on one hand, noncytotoxic concentrations of MCLR had a proinflammatory effect on hepatocytes by inducing the activation of the NF-κB and MAPK pathways and IL-6 expression in a dosedependent manner. Pretreatment with MCLR resulted in a state of cellular hyperresponsiveness toward subsequent stimulation with TNF-α. On the other hand, cytotoxic doses of MCLR resulted in dysfunction of the NF-κB and MAPK signaling pathways and disruption of mitochondria (Fig. 7) . Our study contributes to the elucidation of immunomodulatory role of MCLR in 2 hepatocyte models, PMHs and HepG2 cells, under normal and pre-inflammatory conditions, and lays the ground for research on the possible contribution of MCLR-induced hepatocyte inflammation to MCLR-induced hepatotoxicity. Clarifying the mode of MCLR action on hepatocytes will help improve the protection against MC intoxication.
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